Peru - Spanyol - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

productos roche q.f.s.a. - solucion inyectable - por tableta; metoxipolietilenglicol-epoetina beta 0.040000 mg; - azitromicina

Peru - Spanyol - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

productos roche q.f.s.a. - solucion para inyeccion - por tableta; metoxipolietilenglicol-epoetina beta 0.400000 mg; - propranolol

Peru - Spanyol - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

productos roche q.f.s.a. - solucion para inyeccion - por tableta; metoxipolietilenglicol-epoetina beta 0.600000 mg; - enalapril

Peru - Spanyol - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

productos roche q.f.s.a. - solucion para inyeccion - por vial ; metoxipolietilenglicol-epoetina beta 0.200000 mg; - trastuzumab

Cile - Spanyol - ISPC (Instituto de Salud Pública de Chile)

astrazeneca s.a. - roxadustat - sin formulas

Cile - Spanyol - ISPC (Instituto de Salud Pública de Chile)

astrazeneca s.a. - roxadustat - sin formulas

Cile - Spanyol - ISPC (Instituto de Salud Pública de Chile)

astrazeneca s.a. - roxadustat - sin formulas

Cile - Spanyol - ISPC (Instituto de Salud Pública de Chile)

astrazeneca s.a. - roxadustat - sin formulas

Cile - Spanyol - ISPC (Instituto de Salud Pública de Chile)

astrazeneca s.a. - roxadustat - sin formulas

Uni Eropa - Spanyol - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - clorhidrato de doxorrubicina - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - agentes antineoplásicos - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).